In a video interview with Scrip, Syed Husain, CEO of the US-based cell therapy CDMO BioCentriq, talks about the company’s role in parent GC’s growth strategy and business priorities, the cell and gene therapy manufacturing market and his views on the US BIOSECURE Act.

South Korea is set to provide an additional $18m in support to CEPI amid heighted global worries over mpox. The coalition's CEO and Korea's foreign minister met to discuss strengthened collaboration to prevent and respond to any future pandemics.

As it reported mixed second-quarter earnings, South Korea's pharma industry is increasingly turning to obesity pipeline assets. Meanwhile, leadership disputes among family members within Hanmi are resurfacing.

Artiva grossed $167m by selling more shares than previously planned, but at a significantly lower price per share than it proposed earlier in the week, to fund its NK cell therapy programs.